Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomised Phase II Trial of Sorafenib, Capecitabine and Oxaliplatin (SECOX) Versus Single Agent Sorafenib in Patients With Advanced Hepatocellular Carcinoma

Next Previous
X
Search
Trial Profile

Randomised Phase II Trial of Sorafenib, Capecitabine and Oxaliplatin (SECOX) Versus Single Agent Sorafenib in Patients With Advanced Hepatocellular Carcinoma

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 13 Apr 2020

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Capecitabine (Primary) ; Oxaliplatin (Primary) ; Sorafenib (Primary)
  • Indications Liver cancer
  • Focus Therapeutic Use

    • Most Recent Events

    • 09 Apr 2020 Status changed from active, no longer recruiting to completed.
    • 04 Jun 2019 Results assessing efficacy of sorafenib, capecitabine, and oxaliplatin vs sorafenib in patients with advanced hepatocellular carcinoma, presented at the 55th Annual Meeting of the American Society of Clinical Oncology.
    • 19 Jan 2019 Primary endpoint has not been met. (Time-to-progression (TTP)), as reported in an abstract presented at the 2019 Gastrointestinal Cancers Symposium

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top